LLY

748.91

+3.51%↑

JNJ

177.53

-0.28%↓

ABBV

209.92

+0.22%↑

UNH

333.08

+5.11%↑

NVO

53.23

-2.19%↓

LLY

748.91

+3.51%↑

JNJ

177.53

-0.28%↓

ABBV

209.92

+0.22%↑

UNH

333.08

+5.11%↑

NVO

53.23

-2.19%↓

LLY

748.91

+3.51%↑

JNJ

177.53

-0.28%↓

ABBV

209.92

+0.22%↑

UNH

333.08

+5.11%↑

NVO

53.23

-2.19%↓

LLY

748.91

+3.51%↑

JNJ

177.53

-0.28%↓

ABBV

209.92

+0.22%↑

UNH

333.08

+5.11%↑

NVO

53.23

-2.19%↓

LLY

748.91

+3.51%↑

JNJ

177.53

-0.28%↓

ABBV

209.92

+0.22%↑

UNH

333.08

+5.11%↑

NVO

53.23

-2.19%↓

Search

Editas Medicine Inc

Open

BrancheGesundheitswesen

2.71 -1.81

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.7

Max

2.83

Schlüsselkennzahlen

By Trading Economics

Einkommen

23M

-53M

Verkäufe

-1.1M

3.6M

Gewinnspanne

-1,487.842

Angestellte

246

EBITDA

23M

-49M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+40.58% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

3. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

47M

231M

Vorheriger Eröffnungskurs

4.52

Vorheriger Schlusskurs

2.71

Nachrichtenstimmung

By Acuity

63%

37%

332 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Editas Medicine Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Sept. 2025, 23:59 UTC

Akquisitionen, Fusionen, Übernahmen

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8. Sept. 2025, 22:02 UTC

Wichtige Markttreiber

Microsoft Signs $17.4 Billion AI Deal With Nebius

8. Sept. 2025, 17:01 UTC

Wichtige Markttreiber

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8. Sept. 2025, 17:01 UTC

Wichtige Markttreiber

Tron Shares Rise After New Investment From Bravemorning

8. Sept. 2025, 16:14 UTC

Wichtige Markttreiber

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8. Sept. 2025, 16:13 UTC

Wichtige Markttreiber

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8. Sept. 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Sept. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8. Sept. 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8. Sept. 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8. Sept. 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8. Sept. 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8. Sept. 2025, 21:47 UTC

Wichtige Markttreiber

Microsoft Signs $17.4B AI Deal With Nebius

8. Sept. 2025, 21:33 UTC

Akquisitionen, Fusionen, Übernahmen

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8. Sept. 2025, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8. Sept. 2025, 21:19 UTC

Akquisitionen, Fusionen, Übernahmen

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8. Sept. 2025, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8. Sept. 2025, 20:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

8. Sept. 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8. Sept. 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8. Sept. 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8. Sept. 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Sept. 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8. Sept. 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8. Sept. 2025, 16:59 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8. Sept. 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8. Sept. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8. Sept. 2025, 16:16 UTC

Ergebnisse

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8. Sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. Sept. 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Editas Medicine Inc Prognose

Kursziel

By TipRanks

40.58% Vorteil

12-Monats-Prognose

Durchschnitt 3.88 USD  40.58%

Hoch 6 USD

Tief 1 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Editas Medicine Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

12 ratings

5

Buy

5

Halten

2

Sell

Technischer Score

By Trading Central

1.33 / 1.54Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Neutral Evidence

Langfristig

No Evidence

Stimmung

By Acuity

332 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
help-icon Live chat